News

The Milner Therapeutics Institute has announced Elysium Health as the latest company to become a partner in the Milner Therapeutics Consortium, which brings together the drug development capabilities of pharmaceutical companies with the ideas and know-how of Cambridge academics.The company will also join the Institute's Innovation Board to help def…

R. Derek Finlay, a former student of the University of Cambridge and long-standing donor to Collegiate Cambridge, is donating £5 million to help fund the completion of the new Chemistry of Health building at the Department of Chemistry, and to support research into neurodegenerative diseases.A plaque unveiled by Finlay dedicates the laboratories th…

On 9 March, Vice Chancellor Professor Sir Leszek Borysiewicz and Pro-Vice Chancellor for Research, Professor Chris Abell welcomed an audience of 150 pharmaceutical and biotech company leaders, industry and professional body representatives, and senior academics to hear about the mission and vision of the Cambridge Academy of Therapeutic Sciences (C…

Cambridge Science Festival 2017 kicks off today and the enormous line-up of events looks fantastic as usual. If you’re anything like us, you would need to clone yourself to go to everything you’d like to see. To save you time scouring the whole programme of events, we have pulled together some highlights relevant to the broad area of therapeutics R…

Business Secretary Greg Clark has announced the creation of a new institute named in honour of Rosalind Franklin, whose pioneering use of X-rays to study biological structures played a key role in the discovery of DNA’s ‘double helix’ structure.The institute will have its hub at the Harwell campus near Oxford. It will bring together world-leading s…

Innovate UK and the Research Councils are seeking input from scientists and businesses over the roll out of a £4.7BN cross-disciplinary fund. This will support industry-led programmes of activity aiming to deliver economic impact, jobs and growth. Workshops have been taking place across the country with delegates from the research base and industry…

In January, the Milner Institute announced that Pfizer are the latest partner to join the Milner Therapeutics Consortium, which brings together the drug development capabilities of leading pharmaceutical companies with the ideas and know-how of Cambridge academics.The other existing industrial partners are Astex, AstraZeneca, GlaxoSmithKline, Shion…